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ABSTRACT
Objectives: Unobserved confounding has been suggested to explain the
effect of inﬂuenza vaccination on mortality reported in several observa-
tional studies. An instrumental variable (IV) is strongly related to the
exposure under study, but not directly or indirectly (through other vari-
ables) with the outcome. Theoretically, analyses using IVs to control for
both observed and unobserved confounding may provide unbiased esti-
mates of inﬂuenza vaccine effects. We assessed the usefulness of IV analysis
in inﬂuenza vaccination studies.
Methods: Information on patients aged 65 years and older from the
computerized Utrecht General Practitioner (GP) research database over
seven inﬂuenza epidemic periods was pooled to estimate the association
between inﬂuenza vaccination and all-cause mortality among community-
dwelling elderly. Potential IVs included in the analysis were a history of
gout, a history of orthopaedic morbidity, a history of antacid medication
use, and GP-speciﬁc vaccination rates.
Results: Using linear regression analyses, all possible IVs were associated
with vaccination status: risk difference (RD) 7.8% (95% conﬁdence inter-
val [CI] 3.6%; 12.0%), RD 2.8% (95% CI 1.7%; 3.9%), RD 8.1% (95%
CI 6.1%; 10.1%), and RD 100.0% (95% CI 89.0%; 111.0%) for gout,
orthopaedic morbidity, antacid medication use, and GP-speciﬁc vaccina-
tion rates, respectively. Each potential IV, however, also appeared to be
related to mortality through other observed confounding variables
(notably age, sex, and comorbidity).
Conclusions: The potential IVs studied did not meet the necessary criteria,
because they were (indirectly) associated with the outcome. These vari-
ables may, therefore, not be suited to assess unconfounded inﬂuenza
vaccine effects through IV analysis.
Keywords: bias, confounding, inﬂuenza vaccines, instrumental variable
analysis.
Introduction
Observational studies are prone to confounding bias because
treatment allocation is an inherently nonrandom process [1,2].
Typically in studies on presumed beneﬁcial treatments, patients
with a poorer prognosis tend to receive the treatment. Hence,
treatment effects are biased or confounded by these prognostic
patient characteristics, so-called confounders. Methods such as
matching, stratiﬁcation, and multivariable regression analysis
have been proposed to control for observed confounders. Unob-
served confounders, however, cannot be adjusted for by means of
these methods [1].
Instrumental variables (IVs) can be of use to derive estimates
of treatment effect that are unbiased by both observed and unob-
served confounders [3–6]. An IV is a variable that is strongly
related to the exposure under study, but not with the outcome,
either directly or through an association with confounders.
Although observed confounders can be adjusted for in IV analy-
sis [7] ideally, observed as well as unobserved potential con-
founders should be balanced between groups of subjects with
and without the IV. If observed confounders are balanced
between groups of subjects with and without the IV, the assump-
tion that unobserved confounders are balanced as well seems
more likely. An example of a study in which an IV was used to
estimate a treatment effect is an observational study on inﬂuenza
vaccine effectiveness in which gout was used as an IV [8]. Patients
suffering from gout more often visited their physician and, there-
fore, were more likely to be encouraged (by their physician) to
take the inﬂuenza vaccine. As a result, gout was associated with
inﬂuenza vaccination status. Furthermore, it was assumed that
gout was neither an independent risk factor for the primary
outcome all-cause mortality, nor that it was associated with
potential confounders (e.g., age, sex, and pulmonary and cardio-
vascular diseases) for the association between inﬂuenza vaccina-
tion and mortality.
Within clinical research areas where unobserved confounders
are expected to play a role, IVs may be helpful to produce
unbiased effect estimates. Because results from studies on inﬂu-
enza vaccine effectiveness have been heavily debated, because of
unobserved confounding (e.g., by unobserved functional health
status [9,10]), we planned to study the effectiveness of inﬂuenza
vaccination on all-cause mortality among community-dwelling




An IV is a variable that is strongly related to exposure, yet
independent of the study outcome, given the exposure and poten-
tial confounders [4–6]. This is referred to as the main assumption
for a valid IV which states that an IV should neither directly nor
indirectly (via other variables) be associated with the outcome.
Because observed confounders can be adjusted for in IV analysis,
consequently, the IV should be independent of uncontrolled con-
founding factors. Importantly, if the IV is independent of
observed confounders, it is assumed to be independent of unob-
served confounders. This is in analogy with the comparability of
observed and unobserved prognostic variables between the
Address correspondence to: Rolf H. H. Groenwold, Julius Center for
Health Sciences and Primary Care, University Medical Center Utrecht, PO
Box 85500, 3508GA, Utrecht, TheNetherlands. E-mail: r.h.h.groenwold@
umcutrecht.nl
10.1111/j.1524-4733.2009.00584.x
Volume 13 • Number 1 • 2010
V A L U E I N H E A LT H
132 © 2009, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/10/132 132–137
intervention and control group achieved by randomization in a
trial. As such, the IV method can result in comparability of these
potential confounders between those receiving and those not
receiving the intervention. This so-called pseudo-randomization
on the basis of levels of the IV may indeed, theoretically, guar-
antee absence of confounding. The underlying assumptions,
however, may be difﬁcult to meet for potential IVs [4].
An expert committee (including medical doctors, pharma-
cists, and epidemiologists) was set up to identify potential IVs for
a study on the association between inﬂuenza vaccination and
mortality risk. Based on the aforementioned deﬁnition of an IV,
the proposed variable should be strongly related to vaccination
status and at the same time not be a risk factor for mortality as
well as independent of potential confounders (e.g., age, sex,
pulmonary and cardiovascular diseases, diabetes, etc.). Although
observed confounders could be adjusted for, we aimed for IVs
that were independent of observed confounders, because the
assumption of independence of unobserved confounders would
seem more valid. As in the example using gout as an IV, we
focused on conditions or situations in which we expected sub-
jects more often to visit their physician (hence, were more likely
to be encouraged to take the vaccine). Furthermore, it should be
reasonable to expect that this condition or situation would not
directly or indirectly affect the risk for mortality.
Three groups of potential IVs were distinguished. First, fol-
lowing the study by Yoo and Frick [8], in which gout was used as
an IV, classes of comorbidity were suggested to act as IVs. In
particular, gout and orthopedic morbidity were suggested as IVs.
Patients suffering from gout or orthopedic morbidity more often
visit their physician than patients without this morbidity. Fur-
thermore, it was assumed that both were not a risk factor for
mortality and were not associated with important known and
strong potential confounders as age, sex, diabetes, cancer, and
cardiovascular and pulmonary diseases. A history of gout was
deﬁned as registration of ICPC-code T92 in the 12 months pre-
ceding inﬂuenza vaccination. Registration of an ICPC-code
(L-codes) indicating orthopedic morbidity in the 12 months pre-
ceding inﬂuenza vaccination was deﬁned as presence of the IV
orthopedic morbidity. Possibly, osteoarthritis is associated with
mortality through age. Therefore, additional analyses were
planned in which osteoarthritis was excluded from the deﬁnition
of orthopedic morbidity.
Second, classes of medication were proposed as IVs. Espe-
cially drugs that are prescribed to patients suffering from dys-
pepsia were thought to be related to inﬂuenza vaccination status,
yet unrelated to comorbidity or mortality. Thus, ﬁlling a pre-
scription for antacid medication (ATC-code A02a) in the 12
months preceding inﬂuenza vaccination was deﬁned as presence
of the IV.
Finally, physician characteristics were considered as potential
IVs [11]. Physicians might have speciﬁc preferences with respect
to inﬂuenza vaccination, resulting in varying efforts in persuad-
ing their patients to take the vaccine [12]. Therefore, vaccination
rates among general practitioner (GP) group practices might
differ although, on average, comorbidity distributions can be
assumed to be similar. Furthermore, mortality risk was thought
to be more or less similar across different GP group practices as
well.
Study Population
Information on the potential IVs gout, orthopedic morbidity, use
of antacid medication, and GP group practice speciﬁc vaccina-
tion rates were obtained from the computerized medical database
of The Netherlands University Medical Center Utrecht General
Practitioner Research Network. This database includes cumula-
tive information on approximately 60,000 patients and has
shown to be valid in inﬂuenza vaccine effectiveness studies [13].
The patients are registered with six GP group practices. Until
2007, the Dutch immunization guideline on inﬂuenza vaccina-
tion recommended vaccination for speciﬁc patient groups with
high-risk medical conditions and for all persons aged 65 years
and older. We obtained clinical information on all elderly aged 65
years and older during seven inﬂuenza epidemic periods (1995/
1996–1999/2000, 2001/2002, 2002/2003). Inﬂuenza epidemic
periods were deﬁned as periods of at least two consecutive weeks
in which each week accounted for at least 5% of the season’s
total number of inﬂuenza isolates [14,15]. We excluded the 2000/
2001 winter period because there was virtually no inﬂuenza
activity [14]. This resulted in 44,418 periods of observation. We
collected extensive information on exposure to seasonal inﬂu-
enza vaccination, and on potential confounders such as age and
sex, comorbidity and prior health-care consumption for each
observation period. In the University Medical Center Utrecht
General Practitioner Research Network. all diagnoses are coded
according to the International Classiﬁcation of Primary Care
(ICPC) coding system. Vaccination status was ascertained by
registration of the ICPC-code R44.1, which has shown to accu-
rately reﬂect actual receipt of the vaccine (kappa = 93%) [16].
Comorbidity status was based on registration of ICPC-codes
during the 12 months preceding each year’s inﬂuenza epidemic
period: cardiovascular comorbidity (code K74, K75, K76, K77,
K78-K80, K82-K84, or K90), pulmonary comorbidity (R84,
R85, R91, R95, R96), diabetes (T90), and malignancies (B72,
B73, B74, D74-77, S77, T71, U75-77, X75-77, Y77). Further-
more, health-care consumption (number of GP visits) and medi-
cation use in the year preceding each inﬂuenza epidemic period
were recorded.
Statistical Analyses
For all of the studied potential IVs, similar analyses were per-
formed. First, univariate associations between IVs and inﬂuenza
vaccination status were estimated. Second, univariate associa-
tions between IVs and observed confounders were estimated.
These were compared with univariate associations between inﬂu-
enza vaccination status and observed confounders. Ideally, dis-
tributions of potential confounders are balanced between levels
of the IV and, hence, associations between the IV and potential
confounders are absent (or at least smaller than the associations
between inﬂuenza vaccination and potential confounders) [10].
Finally, the effect of inﬂuenza vaccination on mortality risk was
estimated using the IV. As a ﬁrst step, the association between the
IV and mortality was estimated using linear regression analysis,
thus estimating a risk difference. Then, the association between
the IV and vaccination status was estimated, again using linear
regression analysis. The ratio of these estimates is the risk differ-
ence of the association between inﬂuenza vaccination and mor-
tality risk [4]. The conﬁdence interval (CI) for this risk difference
was estimated by drawing 1000 bootstrap samples of the original
data set and calculating the risk difference in each sample [17].
The 2.5% and 97.5% quintiles of this distribution indicated the
lower and upper bound, respectively, of the 95% CI of the
mortality risk difference between vaccinated and nonvaccinated
subjects.
Even though observed confounders can be adjusted for [7],
unobserved confounders may still bias the association under
study. To quantify the potential impact of unobserved confound-
ing, a sensitivity analysis of unobserved confounding was con-
ducted [18]. First, in the analysis in which gout was used as
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potential IV, observed confounders were adjusted for. Secondly,
an unobserved confounder was simulated and additionally
adjusted for. Smoking status is not routinely reported in the
computerized medical GP database. Therefore, we considered
smoking status to be a potential unobserved confounder. In the
Nurses’ Health Study, current smokers had an almost threefold
increased risk (odds ratio [OR] 2.8) for all-cause mortality as
compared to never-smokers [19]. We considered two scenarios of
smoking status among gout and nongout patients. In the ﬁrst
scenario, 20% of gout patients and 30% of the nongout patients
smoked, whereas in the second scenario 20% of gout patients
and 40% of the nongout patients smoked. Based on these
assumptions, smoking status was simulated and on top of the
observed confounders (i.e., age, sex, and comorbidity status)
included as a confounder in the IV analysis [20]. Analyses were
carried out in SPSS for Windows (version 14.0, SPSS Inc.,
Chicago, IL) and R for Windows (version 2.5.1).
Results
In total, 379 persons died during 44,418 inﬂuenza epidemic
periods of observation. A history of gout was present in 445
periods of observations (1.0%), and was associated with inﬂu-
enza vaccination (OR 1.56; 95% CI 1.23; 1.97). Overall, the
magnitude of the associations between gout and potential con-
founders and the associations between inﬂuenza vaccination and
potential confounders were similar (Table 1). Nevertheless, the
association between gout and presence cardiovascular disease
was stronger than the association between inﬂuenza vaccination
and cardiovascular disease (Table 1). A history of gout increased
the risk for all-cause mortality (risk difference (RD) 0.2%, 95%
CI -0.6% to 1.1%) and was associated with inﬂuenza vaccina-
tion status (RD 7.8%, 95% CI 3.6%; 12.0%). Hence, IV analysis
estimated inﬂuenza vaccination to increase all-cause mortality:
RD = 0.24% / 7.84% = 3.1% (95% CI -8.6% to 17.3%).
The instrumental variable orthopedic morbidity was present
in 7970 periods of observations (17.9%), and was associated
with inﬂuenza vaccination (OR 1.16, 95% CI 1.10; 1.22).
Overall, associations between orthopedic morbidity and poten-
tial confounders were weaker than the associations between
inﬂuenza vaccination status and potential confounders (Table 1).
Male sex, however, had a stronger association with orthopedic
morbidity than with inﬂuenza vaccination status. Orthopedic
morbidity was negatively associated with all-cause mortality
(RD -0.1%, 95% CI -0.3%; 0.1%), although it showed a posi-
tive association with vaccination status (RD 2.8%, 95% CI
1.7%; 3.9%). As a result, IV analysis estimated inﬂuenza vacci-
nation to reduce all-cause mortality (RD -3.8%, 95% CI
-12.5%; 4.0%). In additional analyses, in which osteoarthritis
was excluded from the deﬁnition of orthopedic morbidity, the
association between orthopedic morbidity and age was absent
(OR 1.00, 95% CI 0.98; 1.02). Nevertheless, the associations
between this potential IV and other potential confounders
remained similar (Table 1). Consequently, estimates from IV
analysis were similar as well (RD -2.8%, 95% CI -12.1%;
5.5%).
In the 12 months preceding the inﬂuenza vaccination period,
antacid medication was used in 2013 periods of observations
(4.5%). Use of this type of medication was associated with
inﬂuenza vaccination status (RD 8.1%, 95% CI 6.1%; 10.1%).
The associations between antacid use and potential confounders
on the one hand and the associations between inﬂuenza vaccina-
tion status and potential confounders on the other hand, were of
the same order. IV analysis estimated inﬂuenza vaccination
to increase all-cause mortality (RD 15.9%, 95% CI 10.3%;
23.6%).
Vaccination rates among the six GP group practices ranged
from 68.1% to 77.9% (mean 72.9%). As shown in Table 2,
confounder characteristics were, on average, more balanced
among levels of the IV than among vaccinated and unvacci-
nated subjects (i.e., GP group practices were more similar than
groups of vaccinated and unvaccinated subjects). Nevertheless,
patients were on average older in the GP practice with the
highest vaccination rate. Furthermore, with increasing vaccina-
tion rates, prevalence of cancer tended to increase as well.
Finally, the proportion of males seemed to decrease with
increasing vaccination rate. Trivially, vaccination rate (the IV)
was strongly associated with vaccination status (RD 100.0%,
95% CI 89.0%; 111.0%), although it showed a positive asso-
ciation with all-cause mortality (RD 1.9%, 95% CI -0.4%;
4.2%). As a result, IV analysis estimated inﬂuenza vaccination
to increase all-cause mortality (RD 1.9%, 95% CI -0.6%;
-4.5%).
In Table 3, estimates of inﬂuenza vaccine effectiveness using
IVs are compared with regular analyses (without use of an
IV). Routine analysis showed inﬂuenza vaccination to re-





Associations between observed confounders and . . .
. . . inﬂuenza
vaccination
. . . a history
of gout








. . . a history
of antacid
medication use
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age* 75 (70; 80)† 1.08 (1.06 to 1.09) 1.02 (0.96 to 1.09) 1.03 (1.01 to 1.05) 1.00 (0.98 to 1.02) 1.33 (1.29 to 1.37)
Male sex 38% 1.20 (1.15 to 1.25) 2.06 (1.71 to 2.48) 0.55 (0.52 to 0.58) 0.62 (0.58 to 0.65) 1.45 (1.32 to 1.60)
Presence of cardiovascular disease 10% 1.44 (1.34 to 1.55) 2.11 (1.66 to 2.67) 1.02 (0.94 to 1.11) 1.02 (0.94 to 1.11) 1.43 (1.26 to 1.63)
Presence of pulmonary disease 12% 2.38 (2.20 to 2.58) 1.80 (1.43 to 2.27) 1.07 (0.99 to 1.15) 1.11 (1.02 to 1.20) 1.90 (1.70 to 2.13)
Presence of diabetes mellitus 6.5% 1.98 (1.79 to 2.19) 1.93 (1.45 to 2.58) 0.90 (0.81 to 0.98) 0.92 (0.82 to 1.03) 1.24 (1.05 to 1.47)
Presence of malignancies 2.2% 1.11 (0.96 to 1.28) 0.60 (0.27 to 1.34) 0.95 (0.80 to 1.12) 1.00 (0.83 to 1.20) 1.47 (1.15 to 1.88)
Cardiovascular drug use 47% 1.83 (1.75 to 1.91) 2.64 (2.16 to 3.23) 1.08 (1.03 to 1.13) 1.04 (0.99 to 1.10) 1.81 (1.65 to 1.98)
Pulmonary drug use 11% 2.44 (2.24 to 2.65) 1.86 (1.47 to 2.35) 1.08 (1.00 to 1.16) 1.13 (1.04 to 1.23) 1.99 (1.77 to 2.23)
Diabetic drug use 7.7% 2.28 (2.07 to 2.51) 1.56 (1.17 to 2.09) 0.86 (0.78 to 0.95) 0.90 (0.81 to 1.00) 1.47 (1.27 to 1.70)
Number of GP visits*† 12 (6; 19)† 1.21 (1.20 to 1.23) 1.17 (1.14 to 1.20) 1.16 (1.15 to 1.17) 1.15 (1.14 to 1.16) 1.33 (1.31 to 1.34)
*Odds ratio for age based on 5-year strata, OR for number of GP visits based on strata of ﬁve GP visits.
†Median (interquartile range).
CI, conﬁdence interval to GP, general practitioner to OR, odds ratio.
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duce all-cause mortality risk: unadjusted RD -0.12% (95% CI
-0.31%; 0.07%), and after adjustment for age, sex, comorbidity,
medication use and health-care consumption RD -0.57% (95%
CI -0.77%; -0.38%).
When gout was the IV under study and observed confounders
(i.e., age, sex, and comorbidity status) were adjusted for, IV
analysis estimated inﬂuenza vaccination to reduce all-cause mor-
tality: RD = -0.5% (95% CI: -16.7%; 15.8%). When 20% and
30% of the gout and nongout patients were considered to be a
current smoker, IV analysis estimated inﬂuenza vaccination
to increase all-cause mortality: RD = 1.3% (95% CI: -14.3%;
16.9%). When 20% and 40% of the gout and nongout patients
were considered to be a current smoker, these numbers were:
RD = 2.5% (95% CI: -11.8%; 16.8%).
Discussion
All of the assessed potential IVs to study inﬂuenza vaccine effec-
tiveness did not meet the assumptions of IV analysis. A history of
gout was associated with inﬂuenza vaccination status, as well as
with observed risk factors for mortality. Therefore, gout was
probably not only associated with mortality risk through inﬂu-
enza vaccination, but also through other variables. Hence, it did
not meet the main assumption of IV analysis.
Inﬂuenza vaccination was associated with a reduction in all-
cause mortality risk during inﬂuenza epidemic periods in our
analysis, using orthopedic morbidity as IV. The estimated asso-
ciation, however, was very imprecise, as indicated by the wide
CIs (especially as compared to the CI of the estimate that was
adjusted for observed confounders). Technical reasons for these
wide CIs are the weak association between the IV and vaccina-
tion status and the fact that the CI of a ratio will always be larger
than the CIs of the components of the ratio. Although the asso-
ciations between the IV and most of the observed confounders
were weaker than the associations between vaccination status
and the observed confounders, sex showed a stronger association
with the IV than with vaccination status. Assuming that unob-
served confounders are balanced is, therefore, not self-evident.
Consequently, orthopedic morbidity did not meet the main
assumption of IV analysis, that is independence between the IV
and risk factors for the outcome, and therefore estimates cannot
be considered unbiased. Exclusion of osteoarthritis from the
deﬁnition of orthopedic morbidity did not materially affect these
results.
A history of antacid medication use was associated with
observed confounders and, therefore, it seemed unlikely that
antacid use was not related to the outcome through other vari-
ables (i.e., it did not meet the main assumption of IV analysis).
Finally, GP group practice speciﬁc vaccination rate appeared
also invalid as an IV. Although, confounders were more balanced
among levels of the IV than among vaccinated and unvaccinated
subjects, some confounders still were related to the IV (e.g., age,
sex, and a history of cancer). Thus, the assumption that vacci-
nation rates were not directly related to mortality seems unlikely.
This could also be derived from the observation that the
GP-speciﬁc vaccination rate and vaccination status were nearly
identical, as indicated by the risk difference of 100%. Further-
more, although vaccination rates among the six GP group prac-
tices differed, their range was small (68–78%) and extrapolating
a regression line through these points to the full range of possible
vaccination rates (i.e., 0–100%) results in inaccurate estimates.
This partly explains the wide CI of the IV estimate using
GP-speciﬁc vaccination rate as IV.
To quantify the potential for observed and unobserved con-
founding, the IV analysis using gout as IV was ﬁrst adjusted for
observed confounders and, subsequently, adjusted for a simu-
lated unobserved confounder as well. The direction of the asso-
ciation between inﬂuenza vaccination and mortality risk changed
from positive (crude IV analysis) to negative (adjusted for
observed confounders) and back to a positive association again
(after additional adjustment for a potential unobserved con-
founder). Because the assumptions of the characteristics of the
Table 2 Distribution of confounding characteristics among levels of the instrumental variable GP group practice and among vaccinated and unvaccinated
subjects
Levels of the instrumental variable (GP group practice) Vaccination status
1 2 3 4 5 6 Vaccinated Unvaccinated
Number of subjects 5,156 12,656 3,086 7,494 6,349 9,677 32,388 12,030
Vaccination rate 68.1 69.2 73.0 73.5 76.0 77.9 100 0
Median age (year) 75 74 75 75 73 77 75 74
Proportion (%) male 39.4 41.5 35.8 36.9 40.7 33.5 39.4 35.2
Proportion (%) with cardiovascular disease 7.9 11 9.1 11.8 8.6 10.5 11 7.9
Proportion (%) with pulmonary disease 10 14.8 9.5 11 13.8 10.7 14.3 6.5
Proportion (%) with diabetes 5.2 8 5.2 7.3 7.9 3.8 7.4 3.9
Proportion (%) with cancer 1.8 2.1 2.8 2.8 2.5 3 2.6 2.2
Proportion (%) using cardiovascular drugs 47.4 45.7 46.2 45.9 56 43.6 51 36.2
Proportion (%) using pulmonary drugs 8.9 13.6 8.6 10.3 13.4 9.6 13.2 5.9
Proportion (%) using diabetic drugs 5.9 8.8 6.9 7.1 10 6.4 9 4.2
Median number of GP visits 12 12 10 12 13 11 13 8
GP, general practitioner.
Table 3 Comparison of estimates of the association between inﬂuenza
vaccination and mortality risk adjusted for observed confounders and
instrumental variable (IV) estimates
Risk difference (95% CI)
Regular estimates
Crude association -0.12% (-0.31%; 0.07%)
Adjusted for observed confounders (age,
sex, comorbidity status, medication
use, prior GP visits)
-0.57% (-0.77%; -0.38%)
Instrumental variable estimates
History of gout as IV 3.1% (-8.6%; 17.3%)
History of orthopedic morbidity
(including osteoarthritis) as IV
-3.8% (-12.5%; 4.0%)
History of orthopedic morbidity
(without osteoarthritis) as IV
-2.8% (-12.1%; 5.5%)
History of antacid medication use as IV 15.9% (10.3%; 23.6%)
GP speciﬁc vaccination rate as IV 1.9% (-0.60%; 4.5%)
CI, conﬁdence interval; GP, general practitioner.
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unobserved confounder seem very realistic, the potential for
unobserved confounding appears to be large.
Analyses using IVs seem powerful solutions in observational
studies on the effects of interventions. Nevertheless, in situations
with considerable confounding, the associations between the
exposure under study and potential confounders are strong. As a
result, the association between the exposure and a variable (i.e.,
an IV) that is unrelated to those potential confounders will
diminish [4]. Thus, in situations with considerable confounding,
the association between the IV and the exposure under study will
be weak and the IV cannot be a strong instrument. In The
Netherlands, confounding is known to be an important threat to
the validity of inﬂuenza vaccination studies, indicated by signiﬁ-
cant imbalance of prognostic characteristics among vaccinated
and nonvaccinated subjects and a substantial change in estimate
after adjustment for observed confounders [2,13]. Therefore,
valid IVs to estimate inﬂuenza vaccine effectiveness in The Neth-
erlands seem difﬁcult to obtain.
Still, Yoo and Frick concluded that IV analysis using gout as
an IV is a valid method to control for confounding in studies on
inﬂuenza vaccine effectiveness [8]. They assumed that gout was
only related to mortality through inﬂuenza vaccine effectiveness.
As we previously described, this assumption cannot be tested.
Nevertheless, the strengths of the associations between an IV and
other risk factors for mortality may indicate whether this
assumption seems valid. Unfortunately, Yoo and Frick did not
report these associations. Our data indicated that the potential
IV gout is strongly associated with important risk factors
for mortality such as age, cardiovascular and pulmonary comor-
bidity. Hence, the conclusion that gout is a valid IV seems incor-
rect. Nevertheless, a recently published cohort study on inﬂuenza
vaccine effectiveness among US elderly showed less imbalance of
prognostic characteristics among vaccinated and nonvaccinated
subjects than we found in our data [21]. Therefore, in the United
States, confounding might have less impact on inﬂuenza vacci-
nation studies and valid IVs might be available to estimate inﬂu-
enza vaccine effectiveness.
Nevertheless, in research areas with important confounding,
IVs could still be of use. In such situations, the researcher might be
able to create an IV. For example, to study the effects of maternal
smoking on birth weight, Sexton and Hebel randomly allocated
pregnant women to either an encouragement program to stop
smoking or routine care [22,23]. Because allocation to the
program was a random process, it was unrelated to potential
confounders of the association between maternal smoking and
birth weight. Furthermore, participation in the encouragement
program was associated with a higher degree of smoking cessa-
tion than the routine care group. Under the assumption that the
encouragement program will only affect birth weight through
maternal smoking (and not, for instance, also result in a change of
dietary habits), the encouragement program could act as an IV to
study the association between maternal smoking and birth
weight. Likewise, to study inﬂuenza vaccine effectiveness,
patients could be randomly allocated to either an encouragement
program to take the vaccine or to routine care [24]. As in ran-
domized trials, confounders will be balanced between those fol-
lowing the program and those receiving routine care. To act as an
IV, the encouragement program should then be associated with
higher vaccination rates than in the routine care group (again,
under the assumption that the encouragement program will only
have an effect on the outcome through inﬂuenza vaccination). In
The Netherlands, however, vaccination rates among elderly
(receiving routine care) are already more than 80%, which leaves
little room for improvement [14]. In countries with lower vacci-
nation rates, however, encouragement programs could result in a
considerable increase of vaccination rates and allocation to the
encouragement program could be a valid IV to study inﬂuenza
vaccine effectiveness.
In conclusion, observational intervention studies, such as
studies on inﬂuenza vaccine effectiveness, are prone to confound-
ing bias. IVs are a potential solution for confounding, because IV
analyses control for both observed and unobserved confounders.
The studied IVs, however, did not meet the assumptions of IV
analysis and were therefore inappropriate to study the effects of
inﬂuenza vaccination. In real life, valid IVs to study the effects of
inﬂuenza vaccination may be hard to ﬁnd.
Source of ﬁnancial support: This study is part of a personal grant of Dr. E.
Hak to study confounding in observational intervention studies by the
Netherlands Scientiﬁc Organization (NWO-VENI no. 916.56.109).
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